| V503 in Chinese Girls 9-14 Years Old Versus Chinese Women 20-26 Years Old (V503-071) (NCT05450705) | Merck Sharp & Dohme LLC | 2022-07-22 |
| Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076) (NCT05119855) | Merck Sharp & Dohme LLC | 2022-03-28 |
| Intervention for Human Papillomavirus Vaccine Acceptance in Mexican Mothers (NCT06854354) | Hospital Univeristario Benemerita Universidad Autonoma de Puebla | 2021-12-07 |
| Clinical Effectiveness of PAPILOCARE® in Regression of Cervix HPV Cytological Abnormalities (PAPILOBS GR). (NCT06399341) | Elpen Pharmaceutical Co. Inc. | 2021-09-01 |
| Prevalence and Longitudinal Follow-up of Anal Lesions, HPV Infection and Associated Sexually Transmitted Infections Among Men Who Have Sex With Men in Togo. (NCT04910438) | ANRS, Emerging Infectious Diseases | 2021-06-24 |
| ALA-PDT in Patients With CIN2 in p16-positivity and High-risk HPV Infection (NCT06439433) | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | 2021-05-31 |
| Immunogenicity and Safety of the 9-valent Human Papillomavirus (9vHPV) Vaccine in Japanese Boys and Girls (V503-066) (NCT04772534) | Merck Sharp & Dohme LLC | 2021-05-17 |
| Adjuvant PRGN-2012 in Adult Patients With Recurrent Respiratory Papillomatosis (NCT04724980) | Precigen, Inc | 2021-03-16 |
| Safety and Immunogenicity of Extended 2-dose Regimens of 9-valent Human Papillomavirus (9vHPV) Vaccine (V503-069) (NCT04708041) | Merck Sharp & Dohme LLC | 2021-03-15 |
| Changes in the Prevalence of Oncogenic HPV Types (NCT04671823) | Kanazawa Medical University | 2020-12-01 |
| HPV Infection and Genital Microecology of Childbearing-age Female in China: A Cohort and Multicenter Study (NCT04694495) | Zhujiang Hospital | 2020-11-12 |
| E7 TCR Cell Induction Immunotherapy for Stage II and Stage III HPV-Associated Oropharyngeal Cancer (NCT04015336) | National Cancer Institute (NCI) | 2020-07-06 |
| Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049) (NCT04199689) | Merck Sharp & Dohme LLC | 2020-02-27 |
| Conservative Management in Patients Diagnosed With Grade 2 or Grade 3 CIN (NCT04115787) | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | 2019-10-14 |
| Integrated Cervical Cancer Screening in Mayuge District Uganda (ASPIRE Mayuge) (NCT04000503) | University of British Columbia | 2019-08-01 |
| A Phase II Study of Neoadjuvant E7 TCR T Cell Immunotherapy for Borderline Resectable and Unresectable Stage I HPV-Associated Oropharyngeal Cancer (NCT04044950) | National Cancer Institute (NCI) | 2019-07-29 |
| A Placebo-Controlled Study Using VP-102 in the Treatment of External Genital Warts (NCT03981822) | Verrica Pharmaceuticals Inc. | 2019-06-25 |
| Immunobridging Study of 9- Valent Human Papillomavirus (9vHPV) Vaccine (V503) in Chinese Females 9 to 45 Years of Age (V503-024) (NCT03903562) | Merck Sharp & Dohme LLC | 2019-04-27 |
| Quality of Life After Primary TORS vs IMRT for Patients With Early-stage Oropharyngeal Squamous Cell Carcinoma (NCT04124198) | Christian von Buchwald | 2019-03-01 |
| A Study of Safety, Tolerability and Immunogenicity of HPV-L2 Vaccine in Healthy Adult Male and Female Subjects (NCT03929172) | 2A Pharma AB | 2019-02-28 |
| The KEN SHE Study on HPV-vaccine Efficacy (NCT03675256) | Massachusetts General Hospital | 2018-12-19 |
| Safety and Immunogenicity Study of V503 (GARDASIL™9, 9vHPV Vaccine) Administered to 9- to 26-Year-Old Females and Males in Vietnam (V503-017) (NCT03546842) | Merck Sharp & Dohme LLC | 2018-06-29 |
| Cantharidin and Occlusion in Verruca Epithelium (NCT03487549) | Verrica Pharmaceuticals Inc. | 2018-03-27 |
| E7 TCR T Cells for Human Papillomavirus-Associated Cancers (NCT02858310) | National Cancer Institute (NCI) | 2017-01-27 |
| Community and Physician Perspectives Regarding Male Youth Human Papillomavirus (HPV) Disease and Vaccination (NCT02897232) | Louisiana State University Health Sciences Center Shreveport | 2016-07-01 |
| Safety and Efficacy Study of Topical Ranpirnase to Treat Genital Warts (HPV) (NCT02535104) | Tamir Biotechnology, Inc. | 2016-02-01 |
| Efficacy of VIUSID® Plus GLIZIGEN® in Patients With Papilloma Virus Esophageal (NCT03584308) | Catalysis SL | 2015-10-15 |
| Impact of AV2 Antiviral Drug on the Treatment of HPV-associated Lesions of the Uterine Cervix (NCT02346227) | Jean-Pierre Van geertruyden | 2015-01-01 |
| Human Papillomavirus and Rate of Pregnancy Achieved Via Medically Assisted Procreation (NCT01894425) | Centre Hospitalier Universitaire de Nīmes | 2014-05-01 |
| Impact of HPV Vaccination Against Cervical Lesions and Genital Warts in Colombia. an Ecological Assessment (NCT06700941) | Universidad Nacional de Colombia | 2012-01-01 |
| GARDASIL™ Study in Healthy Females Between 9 and 26 Years of Age in Sub-Saharan Africa (V501-046) (NCT01245764) | Merck Sharp & Dohme LLC | 2011-03-21 |
| Natural History of Human Papillomavirus (HPV) Infections in Mid-Adult Women (WHIM) (NCT01295242) | University of Washington | 2011-02-01 |
| A Study of the Safety, Tolerability, and Immunogenicity of a 9-valent Human Papillomavirus Vaccine ([9vHPV]; V503) Administered to 9- to 15-Year-Old Japanese Girls (V503-008). (NCT01254643) | Merck Sharp & Dohme LLC | 2011-01-12 |
| PApillomavirus in REnal Transplant Patient (NCT02845739) | Centre Hospitalier Universitaire de Besancon | 2011-01-01 |
| A Study of V503 Vaccine Given Concomitantly With REPEVAX™ in 11 to 15 Year Olds (V503-007) (NCT01073293) | Merck Sharp & Dohme LLC | 2010-04-22 |
| Self-collected Swabs for HPV Testing in 18-24 Year Old Women (NCT01101828) | University of Washington | 2010-04-01 |
| Modeling Study to Predict Progression of Anal Cancer Pre-cursor Lesions in HIV (NCT01709448) | National Institute of Allergy and Infectious Diseases (NIAID) | 2009-01-01 |
| An Immunogenicity and Safety Study of Gardasil® in Chinese Subjects (V501-030)(COMPLETED) (NCT00496626) | Merck Sharp & Dohme LLC | 2008-07-20 |
| HPV Infections in Older Women (NCT00743392) | University of Washington | 2008-07-01 |
| Phase I of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + Electroporation for CIN 2 or 3 (NCT00685412) | Inovio Pharmaceuticals | 2008-05-01 |
| GARDASIL™ Post Marketing Surveillance in the Philippines (V501-077) (NCT01355003) | Merck Sharp & Dohme LLC | 2008-02-01 |
| Human Papillomavirus 6/11 in the Lower Airway of Neonates (NCT00549250) | National Taiwan University Hospital | 2007-11-01 |
| Matrix Metalloproteinases and Human Papillomavirus in Dysplasias and Cancers of the Cervix (NCT04072913) | University Hospital, Bordeaux | 2007-10-10 |
| Gardasil Vaccination as Therapy in Low Grade Cervical Abnormalities (NCT00501189) | Eisenhower Army Medical Center | 2007-08-01 |
| Safety, Tolerability and Immunogenicity of HPV (Human Papilloma Virus) Vaccine in Healthy Females 9 to 15 Years of Age in India (V501-029) (NCT00380367) | Merck Sharp & Dohme LLC | 2007-05-03 |
| High-Risk HPV Infections in Women Aged 25 to 65 (NCT00461877) | University of Washington | 2007-03-01 |
| Efficacy of 851B Gel for Treating High-Risk Cervical Human Papillomavirus Infection in Women. (NCT00117884) | Takeda | 2006-04-01 |
| Efficacy of 851B Gel for Treating High-Risk Cervical Human Papillomavirus Infection in Women. (NCT00312286) | Takeda | 2006-04-01 |
| Oral Human Papillomavirus Infection in HIV-infected Men (NCT00421486) | Deutsche Luft und Raumfahrt | 2006-03-01 |
| Human Papillomavirus (HPV) Registration Study (Gardasil)(V501-023)(COMPLETED) (NCT00157950) | Merck Sharp & Dohme LLC | 2005-10-01 |
| Human Papillomavirus (HPV) Infection in Pregnancy (NCT00194311) | University of Pennsylvania | 2005-04-01 |
| A Study of Gardasil (V501) in Preadolescents and Adolescents (V501-018) (NCT00092547) | Merck Sharp & Dohme LLC | 2003-10-08 |
| Viral Load Determination and Biomarkers of High Risk Human Papillomavirus (HPV) - Types in HIV-positive Men (NCT00365729) | Deutsche Luft und Raumfahrt | 2003-10-01 |
| Trial of Male Circumcision: HIV, Sexually Transmitted Disease (STD) and Behavioral Effects in Men, Women and the Community (NCT00124878) | Wawer, Maria J., M.D. | 2003-08-01 |
| Screening for HIV-Associated Anal Cancer (NCT00188292) | University Health Network, Toronto | 2002-08-01 |
| Dose-Ranging Study of Quadrivalent Human Papillomavirus (HPV) (Types 6,11,16,18) L1 Virus-Like Particle (VLP) Vaccine (V501-007)(COMPLETED) (NCT00365716) | Merck Sharp & Dohme LLC | 2000-05-01 |